These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 7482224)

  • 1. Guillain-Barré syndrome: clinical and immunological aspects.
    Rostami AM
    Springer Semin Immunopathol; 1995; 17(1):29-42. PubMed ID: 7482224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular immunity in inflammatory autoimmune neuropathies.
    Mäurer M; Toyka KV; Gold R
    Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S7-15. PubMed ID: 12690655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome.
    Zhu J; Mix E; Link H
    J Neuroimmunol; 1998 Apr; 84(1):40-52. PubMed ID: 9600707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I.
    Hartung HP; Pollard JD; Harvey GK; Toyka KV
    Muscle Nerve; 1995 Feb; 18(2):137-53. PubMed ID: 7823972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can IFN-γ be a therapeutic target in Guillain-Barré syndrome?
    Zhang HL; Wu L; Wu X; Zhu J
    Expert Opin Ther Targets; 2014 Apr; 18(4):355-63. PubMed ID: 24479493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into Campylobacter jejuni-induced Guillain-Barré syndrome from the Lewis rat model of experimental allergic neuritis.
    Vriesendorp FJ
    J Infect Dis; 1997 Dec; 176 Suppl 2():S164-8. PubMed ID: 9396704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effector mechanisms of PNS demyelination in Gal-C induced-EAN].
    Saida K
    Rinsho Shinkeigaku; 1990 Dec; 30(12):1361-3. PubMed ID: 2129197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance and susceptibility to experimental autoimmune neuritis in Sprague-Dawley and Lewis rats correlate with different levels of autoreactive T and B cell responses to myelin antigens.
    Zhu J; Zou LP; Bakhiet M; Mix E
    J Neurosci Res; 1998 Nov; 54(3):373-81. PubMed ID: 9819142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis.
    Zhang HL; Zheng XY; Zhu J
    Cytokine Growth Factor Rev; 2013 Oct; 24(5):443-53. PubMed ID: 23791985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of experimental autoimmune neuritis by an antibody to the lymphocyte function-associated antigen-1.
    Archelos JJ; Mäurer M; Jung S; Miyasaka M; Tamatani T; Toyka KV; Hartung HP
    Lab Invest; 1994 May; 70(5):667-75. PubMed ID: 8196363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipooligosaccharide of Campylobacter jejuni prevents myelin-specific enteral tolerance to autoimmune neuritis--a potential mechanism in Guillain-Barre syndrome?
    Jung S; Zimmer S; Lüneberg E; Frosch M; Karch H; Korn T; Toyka KV
    Neurosci Lett; 2005 Jun 10-17; 381(1-2):175-8. PubMed ID: 15882812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of experimental autoimmune neuritis by nasal administration of P2 protein peptide 57-81.
    Zhu J; Deng GM; Levi M; Wahren B; Diab A; van der Meide PH; Link H
    J Neuropathol Exp Neurol; 1998 Mar; 57(3):291-301. PubMed ID: 9600221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of Rolipram in experimental autoimmune neuritis: protection is associated with down-regulation of IFN-gamma and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous system.
    Abbas N; Zou LP; Pelidou SH; Winblad B; Zhu J
    Autoimmunity; 2000 Sep; 32(2):93-9. PubMed ID: 11078155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with P2 protein peptide 57-81 by nasal route is effective in Lewis rat experimental autoimmune neuritis.
    Zou LP; Zhu J; Deng GM; Levi M; Wahren B; Diab A; Hillert J; Link H
    J Neuroimmunol; 1998 May; 85(2):137-45. PubMed ID: 9630162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome.
    Hartung HP; Toyka KV
    Ann Neurol; 1990; 27 Suppl():S57-63. PubMed ID: 2194429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell directed immunotherapy of inflammatory demyelination in the peripheral nervous system. Potent suppression of the effector phase of experimental autoimmune neuritis by anti-CD2 antibodies.
    Jung S; Toyka K; Hartung HP
    Brain; 1996 Aug; 119 ( Pt 4)():1079-90. PubMed ID: 8813272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of production of MIP-1alpha, MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation of immune responses during experimental autoimmune neuritis in Lewis rats.
    Zou LP; Pelidou SH; Abbas N; Deretzi G; Mix E; Schaltzbeerg M; Winblad B; Zhu J
    J Neuroimmunol; 1999 Aug; 98(2):168-75. PubMed ID: 10430050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal serum factors in Guillain-Barré syndrome.
    Lisak RP; Brown MJ; Summer AJ
    Ital J Neurol Sci; 1983 Sep; 4(3):265-72. PubMed ID: 6358121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2-reactive T cells in inflammatory demyelination of the peripheral nerve.
    Rostami AM
    J Infect Dis; 1997 Dec; 176 Suppl 2():S160-3. PubMed ID: 9396703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guillain-Barré as an autoimmune disease.
    Shoenfeld Y; George J; Peter JB
    Int Arch Allergy Immunol; 1996 Apr; 109(4):318-26. PubMed ID: 8634515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.